References
- Gómez CA, Kleinman DV, Pronk N, et al. Addressing health equity and social determinants of health through healthy people 2030. J Public Health Manag Pract. 2021;27(Suppl 6):S249–S257. doi:10.1097/PHH.0000000000001297
- Snowden LR, Graaf G, Keyes L, et al. Did Medicaid expansion close African American-white health care disparities nationwide? A scoping review. BMC Public Health. 2022;22(1):1638. doi:10.1186/s12889-022-14033-8
- Pathak EB. Mortality among black men in the USA. J Racial Ethn Health Disparities. 2018;5(1):50–61. doi:10.1007/s40615-017-0341-5
- DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211–233. doi:10.3322/caac.21555
- National Cancer Institute. Compare cancer sites: SEER 5-year age-adjusted incidence rates, 2015-2019. 2022.(Accessed November 15, 2022). Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=9999&data_type=1&graph_type=10&compareBy=site&chk_site_83=83&chk_site_90=90&chk_site_89=89&chk_site_86=86&series=race&chk_race_9=9&chk_race_8=8&chk_race_3=3&chk_race_2=2&sex=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=1.
- Fillmore NR, Yellapragada SV, Ifeorah C, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133(24):2615–2618. doi:10.1182/blood.2019000406
- Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501–5506. doi:10.1182/blood-2010-07-298760
- Abouzaid S, Parikh K, Zhou Z-Y, et al. Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM). J Clin Oncol. 2016;34(Suppl 15?):8022–8022. doi:10.1200/JCO.2016.34.15_suppl.8022
- Ailawadhi S, Frank RD, Advani P, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017;6(12):2876–2885. doi:10.1002/cam4.1246
- Fiala MA, Wildes TM, Vij R. Racial disparities in the utilization of novel agents for frontline treatment of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(10):647–651. doi:10.1016/j.clml.2020.04.018
- Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158(1):91–98. doi:10.1111/j.1365-2141.2012.09124.x
- Ailawadhi S, Frank RD, Sharma M, et al. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the medicare population: a comprehensive look at racial disparities. Cancer. 2018;124(8):1710–1721. doi:10.1002/cncr.31237
- Ailawadhi S, Jagannath S, Lee HC, et al. Association between race and treatment patterns and survival outcomes in multiple myeloma: a connect MM registry analysis. Cancer. 2020;126(19):4332–4340. doi:10.1002/cncr.33089
- Sonderman JS, Bethea TN, Kitahara CM, et al. Multiple myeloma mortality in relation to obesity among African Americans. J Natl Cancer Inst. 2016;108(10):djw120. doi:10.1093/jnci/djw120
- Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. 2020. (Accessed November 7, 2022). Available from: https://arxiv.org/abs/2001.09765.
- Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron Health, SEER, and NPCR. 2020.(Accessed November 7, 2022). Available from: https://doi.org/10.1101/2020.03.16.20037143.
- Ailawadhi S, Jacobus S, Sexton R, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the cooperative group clinical trials. Blood Cancer J. 2018;8(7):67. doi:10.1038/s41408-018-0102-7